{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:32:49Z","timestamp":1786120369785,"version":"build-2736575974"},"reference-count":44,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1097\/mpa.0b013e318249d62e","type":"journal-article","created":{"date-parts":[[2012,4,18]],"date-time":"2012-04-18T07:54:30Z","timestamp":1334735670000},"page":"1048-1057","source":"Crossref","is-referenced-by-count":26,"title":["Enhanced Antitumor Effect of Combination Therapy With Gemcitabine and Guggulsterone in Pancreatic Cancer"],"prefix":"10.1097","volume":"41","author":[{"given":"Dong-Won","family":"Ahn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong Kyun","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Hyub","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Hyeok","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun Kyu","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Kon","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Tae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong Bum","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-9-20210212","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3322\/caac.20073","article-title":". Cancer statistics, 2010.","volume":"60","author":"Jemal","year":"2010","journal-title":"CA Cancer J Clin"},{"key":"R2-9-20210212","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1001\/jama.297.3.267","article-title":". Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.","volume":"297","author":"Oettle","year":"2007","journal-title":"JAMA"},{"key":"R3-9-20210212","first-page":"313","article-title":"Updates in locally advanced pancreatic cancer. Highlights from the 2010 ASCO Annual Meeting. Chicago, IL, USA. June 4-8, 2010.","volume":"11","author":"Chang","year":"2010","journal-title":"JOP"},{"key":"R4-9-20210212","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","article-title":"3rd, Moore MJ, Andersen J, et al.. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.","volume":"15","author":"Burris","year":"1997","journal-title":"J Clin Oncol"},{"key":"R5-9-20210212","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1002\/cncr.10753","article-title":"New applications of gemcitabine and future directions in the management of pancreatic cancer.","volume":"95","author":"Abbruzzese","year":"2002","journal-title":"Cancer"},{"key":"R6-9-20210212","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/bjc.1996.18","article-title":". Phase II study of gemcitabine in patients with advanced pancreatic cancer.","volume":"73","author":"Carmichael","year":"1996","journal-title":"Br J Cancer"},{"key":"R7-9-20210212","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1200\/JCO.2002.11.149","article-title":". Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.","volume":"20","author":"Berlin","year":"2002","journal-title":"J Clin Oncol"},{"key":"R8-9-20210212","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1200\/JCO.2006.09.0886","article-title":". Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group.","volume":"25","author":"Herrmann","year":"2007","journal-title":"J Clin Oncol"},{"key":"R9-9-20210212","doi-asserted-by":"crossref","first-page":"5513","DOI":"10.1200\/JCO.2009.24.2446","article-title":". Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer.","volume":"27","author":"Cunningham","year":"2009","journal-title":"J Clin Oncol"},{"key":"R10-9-20210212","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1200\/JCO.2009.25.4433","article-title":". Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study.","volume":"28","author":"Colucci","year":"2010","journal-title":"J Clin Oncol"},{"key":"R11-9-20210212","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/sj.bjc.6603301","article-title":". A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer.","volume":"95","author":"Stathopoulos","year":"2006","journal-title":"Br J Cancer"},{"key":"R12-9-20210212","doi-asserted-by":"crossref","first-page":"3778","DOI":"10.1200\/JCO.2008.20.9007","article-title":". Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group.","volume":"27","author":"Poplin","year":"2009","journal-title":"J Clin Oncol"},{"key":"R13-9-20210212","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1200\/JCO.2006.07.9525","article-title":". Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.","volume":"25","author":"Moore","year":"2007","journal-title":"J Clin Oncol"},{"key":"R14-9-20210212","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/j.1749-6632.2002.tb04671.x","article-title":"Chemopreventive agents induce suppression of nuclear factor-kappaB leading to chemosensitization.","volume":"973","author":"Bharti","year":"2002","journal-title":"Ann N Y Acad Sci"},{"key":"R15-9-20210212","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1039\/b801558a","article-title":"Chemopreventive effects of natural dietary compounds on cancer development.","volume":"37","author":"Pan","year":"2008","journal-title":"Chem Soc Rev"},{"key":"R16-9-20210212","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/MPA.0b013e318193a074","article-title":". The flavonoid apigenin potentiates the growth inhibitory effects of gemcitabine and abrogates gemcitabine resistance in human pancreatic cancer cells.","volume":"38","author":"Strouch","year":"2009","journal-title":"Pancreas"},{"key":"R17-9-20210212","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.canlet.2007.09.015","article-title":". Enhanced anti-tumor effect of combination therapy with gemcitabine and apigenin in pancreatic cancer.","volume":"259","author":"Lee","year":"2008","journal-title":"Cancer Lett"},{"key":"R18-9-20210212","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1002\/ijc.24628","article-title":". Fisetin, a natural flavonoid, targets chemoresistant human pancreatic cancer AsPC-1 cells through DR3-mediated inhibition of NF-kappaB.","volume":"125","author":"Murtaza","year":"2009","journal-title":"Int J Cancer"},{"key":"R19-9-20210212","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1158\/0008-5472.CAN-06-4257","article-title":". Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products.","volume":"67","author":"Kunnumakkara","year":"2007","journal-title":"Cancer Res"},{"key":"R20-9-20210212","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1146\/annurev.nutr.23.011702.073102","article-title":"GUGULIPID: a natural cholesterol-lowering agent.","volume":"23","author":"Urizar","year":"2003","journal-title":"Annu Rev Nutr"},{"key":"R21-9-20210212","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S1043-2760(02)00640-9","article-title":"Guggulsterone: an old approach to a new problem.","volume":"13","author":"Sinal","year":"2002","journal-title":"Trends Endocrinol Metab"},{"key":"R22-9-20210212","first-page":"267","article-title":". Antiarthritic and anti-inflammatory activity of gum guggul (Balsamodendron mukul Hook).","volume":"4","author":"Gujral","year":"1960","journal-title":"Indian J Physiol Pharmacol"},{"key":"R23-9-20210212","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0006-291X(03)00551-5","article-title":"Guggulsterone antagonizes farnesoid X receptor induction of bile salt export pump but activates pregnane X receptor to inhibit cholesterol 7alpha-hydroxylase gene.","volume":"304","author":"Owsley","year":"2003","journal-title":"Biochem Biophys Res Commun"},{"key":"R24-9-20210212","doi-asserted-by":"crossref","first-page":"47148","DOI":"10.1074\/jbc.M408093200","article-title":"Guggulsterone inhibits NF-kappaB and IkappaBalpha kinase activation, suppresses expression of anti-apoptotic gene products, and enhances apoptosis.","volume":"279","author":"Shishodia","year":"2004","journal-title":"J Biol Chem"},{"key":"R25-9-20210212","doi-asserted-by":"crossref","first-page":"10057","DOI":"10.1073\/pnas.94.19.10057","article-title":". Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-kappaB control.","volume":"94","author":"Chu","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R26-9-20210212","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1101\/gad.13.4.382","article-title":". The prosurvival Bcl-2 homolog Bfl-1A1 is a direct transcriptional target of NF-kappaB that blocks TNFalpha-induced apoptosis.","volume":"13","author":"Zong","year":"1999","journal-title":"Genes Dev"},{"key":"R27-9-20210212","doi-asserted-by":"crossref","first-page":"3964","DOI":"10.1128\/MCB.21.12.3964-3973.2001","article-title":". NF-kappaB inducers upregulate cFLIP, a cycloheximide-sensitive inhibitor of death receptor signaling.","volume":"21","author":"Kreuz","year":"2001","journal-title":"Mol Cell Biol"},{"key":"R28-9-20210212","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.bcp.2007.03.026","article-title":". Guggulsterone inhibits tumor cell proliferation, induces S-phase arrest, and promotes apoptosis through activation of c-Jun N-terminal kinase, suppression of Akt pathway, and downregulation of antiapoptotic gene products.","volume":"74","author":"Shishodia","year":"2007","journal-title":"Biochem Pharmacol"},{"key":"R29-9-20210212","doi-asserted-by":"crossref","first-page":"7439","DOI":"10.1158\/0008-5472.CAN-07-0120","article-title":". Guggulsterone-induced apoptosis in human prostate cancer cells is caused by reactive oxygen intermediate dependent activation of c-Jun NH2-terminal kinase.","volume":"67","author":"Singh","year":"2007","journal-title":"Cancer Res"},{"key":"R30-9-20210212","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1158\/1535-7163.MCT-05-0223","article-title":". Caspase-dependent apoptosis induction by guggulsterone, a constituent of Ayurvedic medicinal plant Commiphora mukul, in PC-3 human prostate cancer cells is mediated by Bax and Bak.","volume":"4","author":"Singh","year":"2005","journal-title":"Mol Cancer Ther"},{"key":"R31-9-20210212","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.canlet.2009.01.026","article-title":". Guggulsterone induces apoptosis in colon cancer cells and inhibits tumor growth in murine colorectal cancer xenografts.","volume":"279","author":"An","year":"2009","journal-title":"Cancer Lett"},{"key":"R32-9-20210212","first-page":"2926","article-title":". Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma.","volume":"60","author":"Bruns","year":"2000","journal-title":"Cancer Res"},{"key":"R33-9-20210212","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/nrc776","article-title":"Death and anti-death: tumour resistance to apoptosis.","volume":"2","author":"Igney","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"R34-9-20210212","first-page":"F1","article-title":". Apoptosis regulators and their role in tumorigenesis.","volume":"1551","author":"Zornig","year":"2001","journal-title":"Biochim Biophys Acta"},{"key":"R35-9-20210212","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1080\/078538902321012405","article-title":"Induction of apoptosis in cancer: new therapeutic opportunities.","volume":"34","author":"Ding","year":"2002","journal-title":"Ann Med"},{"key":"R36-9-20210212","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/bcr596","article-title":"p27KIP1 phosphorylation by PKBAkt leads to poor breast cancer prognosis.","volume":"5","author":"Clarke","year":"2003","journal-title":"Breast Cancer Res"},{"key":"R37-9-20210212","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/sj.leu.2402824","article-title":". Involvement of PI3KAkt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy.","volume":"17","author":"Chang","year":"2003","journal-title":"Leukemia"},{"key":"R38-9-20210212","first-page":"989","article-title":". Inhibition of the phosphatidylinositol 3-kinase-AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo.","volume":"1","author":"Bondar","year":"2002","journal-title":"Mol Cancer Ther"},{"key":"R39-9-20210212","doi-asserted-by":"crossref","first-page":"8339","DOI":"10.1158\/0008-5472.CAN-05-0121","article-title":". Inhibition of the phosphatidylinositol 3-kinaseAkt pathway by inositol pentakisphosphate results in antiangiogenic and antitumor effects.","volume":"65","author":"Maffucci","year":"2005","journal-title":"Cancer Res"},{"key":"R40-9-20210212","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1207\/s15327914nc4801_12","article-title":"Inactivation of akt and NF-kappaB play important roles during indole-3-carbinol-induced apoptosis in breast cancer cells.","volume":"48","author":"Rahman","year":"2004","journal-title":"Nutr Cancer"},{"key":"R41-9-20210212","first-page":"2369","article-title":"Inhibition of nuclear factor kappaB activation in PC3 cells by genistein is mediated via Akt signaling pathway.","volume":"8","author":"Li","year":"2002","journal-title":"Clin Cancer Res"},{"key":"R42-9-20210212","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/ijc.11679","article-title":". Resistance of pancreatic cancer to gemcitabine treatment is dependent on mitochondria-mediated apoptosis.","volume":"109","author":"Schniewind","year":"2004","journal-title":"Int J Cancer"},{"key":"R43-9-20210212","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s10434-999-0279-x","article-title":"Gemcitabine-induced programmed cell death (apoptosis) of human pancreatic carcinoma is determined by Bcl-2 content.","volume":"6","author":"Bold","year":"1999","journal-title":"Ann Surg Oncol"},{"key":"R44-9-20210212","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1007\/s00280-002-0435-5","article-title":". Overexpression of Bax sensitizes human pancreatic cancer cells to apoptosis induced by chemotherapeutic agents.","volume":"49","author":"Xu","year":"2002","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Pancreas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00006676-201210000-00009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:36:10Z","timestamp":1786048570000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00006676-201210000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":44,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/mpa.0b013e318249d62e","relation":{},"ISSN":["0885-3177"],"issn-type":[{"value":"0885-3177","type":"print"}],"subject":[],"published":{"date-parts":[[2012,10]]}}}